Evalstotug

埃沃苏塔单抗

Report date: 2023/12/28 17:49:38

Base Information

Drug NameEvalstotug
Drug Alias NameCAB-CTLA-4BA-3071
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsT lymphocytes stimulants
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsCarcinoma, Non-Small-Cell LungMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesBioAtla IncBeOne Medicines Ltd
China Registration ClassN/A

Develop Information

Active CompaniesBeOne Medicines LtdBioAtla Inc
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell LungMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A